Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG-Reference-Cited by-同舟云学术

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG

Published:2022-01 Issue:1 Volume:40 Page:9.e1-9.e7
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Steinberg Ryan L.,Packiam Vignesh T.,Thomas Lewis J.,Brooks Nathan,Vitale Andrew,Mott Sarah L,Crump Trafford,Wang Jonathan,DeWolf William C.,Lamm Donald L,Kates Max,Hyndman M. Eric,Kamat Ashish M.,Bivalacqua Trinity J.,Nepple Kenneth G.,O'Donnell Michael A.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update;Babjuk;European urology,2019

2. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline;Chang;J Urol,2016

3. Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

4. Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group;Kamat;J Clin Oncol,2016

5. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG;Lerner;Bladder Cancer.,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23

2. Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor;Cancers;2024-07-17

3. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?;Expert Opinion on Pharmacotherapy;2024-01-22

4. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition;Urologic Oncology: Seminars and Original Investigations;2023-12

5. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2023-10-19